Emami

EMAMILTD closed at ₹387.50 on 2026-11-06, trading within a narrow range between ₹380.10 and ₹392.90. The technical setup is characterized by a conflict between short-term price positioning and longer-term trend structure. On the daily chart, the stock remains above its 20-day and 50-day moving averages but is firmly below the 200-day SMA and Supertrend, which are bearish. Momentum indicators show weakness: the Daily ADX is low at 13.44, indicating a lack of strong directional conviction, while the Plus DI (20.98) exceeds the Minus DI (12.9), suggesting mild bullish pressure despite the broader downtrend.

Weekly and monthly horizons reinforce the bearish bias, with prices below all major moving averages and Supertrends on both timeframes. The monthly ADX stands at 25.25, indicating an established downward trend. Recent activity includes an extreme volume-backed upward move on 2026-11-05 (+1.8%) followed by a moderate weekly downward gap on 2026-11-06 (-0.1%). An active 'Inside Bar' pattern on the daily chart signals consolidation. The stock is near the upper end of its 20-day range (+84.4%) but near the lower end of its 252-day range (+15.7%), with a significant current drawdown of -40.1% from available highs.

Emami Ltd reported consolidated revenue of ₹1,088 crore for Q2 FY27, marking a 36% year-on-year increase driven by strong domestic volume growth and positive trends in its winter portfolio. Despite this top-line expansion, net profit declined by 2–3%, attributed to the normalization of the effective tax rate following the phase-out of fiscal incentives and higher input costs linked to geopolitical tensions in West Asia. To offset rising costs, the company has implemented price hikes while maintaining a focus on cost-efficiency.

Strategically, Emami is leveraging established brand trust to expand into new categories such as protein nutrition and health-focused snacks. The company is also pursuing acquisitions of premium digital-first consumer brands, noting that strategic investments like SkinKraft and Vedix now account for over a quarter of its India sales. Following these results, the board declared an interim dividend of ₹5 per share (a 500% payout ratio) with a record date of November 13, 2026. Shares rose 3% post-results, though external analysis notes that margins require improvement to keep pace with the accelerated growth.

Emami Limited reported Q2 FY27 results on November 5, 2026, showing a 36% year-on-year increase in consolidated revenue to ₹1,088 crore, driven by strong domestic volume growth and its winter portfolio. However, profit after tax declined by 2-3%, attributed to the normalization of the effective tax rate following the phase-out of fiscal incentives and higher input costs linked to geopolitical tensions. The board declared an interim dividend of ₹5 per share (a 500% payout) with a record date of November 13, 2026. Concurrently, the company appointed Debendra Banthiya as Company Secretary and Compliance Officer effective November 5, 2026, and designated specific Key Managerial Personnel for disclosure authorizations. Strategically, Emami is leveraging brand trust to expand into protein nutrition and specialized hair care, while pursuing acquisitions of digital-first brands like SkinKraft and Vedix, which now contribute over 25% of India sales.

Emami Limited’s Board approved unaudited financial results for Q2 and H1 FY27 (ended September 30, 2026) on November 5, 2026. Consolidated revenue grew 36% to ₹1,088 crore in Q2, driven by a 49% surge in Domestic Business volume. EBITDA increased 25% to ₹222 crore, while Profit After Tax (PAT) declined 3% to ₹144 crore due to tax rate normalization. The company declared a first interim dividend of ₹5 per equity share (500% on face value), with a record date of November 13, 2026, and payment by December 4, 2026. Additionally, the Board completed a share buyback worth ₹281.24 crore involving 73 lakh shares. Consolidated results include impacts from recent acquisitions: Axiom Ayurveda Pvt. Ltd. (subsidiary since April 1, 2026) and IncNut Digital Pvt. Ltd. (subsidiary since June 1, 2026). The statutory auditor issued a qualified conclusion regarding one unreviewed subsidiary component.

Emami (EMAMILTD) reported a sharp sequential recovery in Q2 FY2026-27, with revenue from operations nearly doubling to ₹2,127 crore and net profit rising 104% to ₹284 crore compared to Q1. This follows a period of contraction, evidenced by a -10% year-on-year sales decline in Sep 2025 and a TTM compounded profit growth of -7%. Despite the recent quarterly rebound, the stock has underperformed over longer horizons, with a 3-year price CAGR of -9% and a 10-year CAGR of -4%, contrasting with strong historical profitability metrics like a 5-year ROE of 31%.

Financial health shows mixed signals. While operating cash flow conversion remains robust at 101% of operating profit in Mar 2026, borrowings have surged significantly, with total borrowings jumping from ₹90 crore in Mar 2025 to ₹162 crore in Mar 2026. Current liabilities also increased sharply to ₹1,050 crore as of Sep 2026, while current assets decreased slightly to ₹1,825 crore. Cash on hand fell to ₹47.4 crore, though bank balances excluding cash rose to ₹206 crore. Promoter holding remained stable at 54.84%, but FII participation declined to 9.02%.

Emami’s Q2 FY27 results highlight a bifurcation between top-line momentum and bottom-line pressure, offering a conditional upside case centered on strategic portfolio expansion. Consolidated revenue surged 36% year-on-year to ₹1,088 crore, driven by strong domestic volume growth and positive winter portfolio trends. A key constructive signal is the rapid scaling of digital-first brands; strategic investments in SkinKraft and Vedix now account for over a quarter of India sales, positioning the company to capitalize on shifting consumer preferences alongside rivals like Marico and Hindustan Unilever. The board’s declaration of an interim dividend of ₹5 per share (a 500% payout ratio) further underscores management confidence in cash generation despite headwinds. However, this growth narrative is currently tempered by margin compression: net profit fell 2–3% due to higher input costs from West Asia conflicts and the normalization of tax rates following the phase-out of fiscal incentives. The constructive case holds only if the company can successfully offset inflationary pressures through price hikes while maintaining cost-efficiency, allowing margins to catch up with the accelerating revenue engines.

Emami Ltd faces a challenging investment setup characterized by significant margin pressure and prolonged technical weakness. While consolidated revenue surged 36% year-on-year to ₹1,088 crore in Q2 FY27, profit after tax declined by 2-3%. This divergence stems from the normalization of the effective tax rate following the phase-out of fiscal incentives and rising input costs linked to geopolitical tensions in West Asia. Persistent inflationary pressures have forced price hikes that have not yet fully offset cost escalations, indicating that top-line growth is currently outpacing profitability.

Market sentiment reflects these fundamental headwinds alongside broader macroeconomic constraints. The stock has underperformed significantly over the past year, with returns down 25.9% and a year-to-date decline of 26.2%. Technical indicators reinforce this caution: the daily, weekly, and monthly Supertrend directions are all bearish. The stock is trading near its pivot support at ₹385.50, with immediate resistance overhead at ₹395.70 (2.12% above). Furthermore, the company is currently in a deep drawdown phase, with a current drawdown of -40.1% against a maximum drawdown of -44.4%, suggesting limited short-term momentum despite the interim dividend declaration.